Glaxo Ebola vax shows no adverse effects so far in first human trial

NIAID Director Dr. Anthony Fauci

With the Ebola death toll mounting in West Africa, a Phase I trial of GlaxoSmithKline's ($GSK) experimental vaccine for the disease is underway at the U.S. National Institutes of Health. And so far, health officials have no bad news to report. At a congressional hearing this week, Dr. Anthony Fauci, director of the NIH's National Institute of Allergy and Infectious Diseases (NIAID), told legislators that the study has so far produced no major side effects so far in healthy volunteers. More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.